Genetic predisposition to sarcoidosis
J Autoimmun. 2023 Oct 19:103122. doi: 10.1016/j.jaut.2023.103122. Online ahead of print.ABSTRACTSarcoidosis is a complex systemic disease with clinical heterogeneity based on varying phenotypes and natural history. The detailed etiology of sarcoidosis remains unknown, but genetic predisposition as well as environmental exposures play a significant role in disease pathogenesis. We performed a comprehensive review of germline genetic (DNA) and transcriptomic (RNA) studies of sarcoidosis, including both previous studies and more recent findings. In this review, we provide an assessment of the following: genetic variants in sa...
Source: Journal of Autoimmunity - October 21, 2023 Category: Allergy & Immunology Authors: Shu-Yi Liao Tasha Fingerlin Lisa Maier Source Type: research
Pulmonary sarcoidosis: A comprehensive review: Past to present
CONCLUSION: The mortality rate for sarcoidosis over a 5 year follow up is approximately 7%. Unfortunately, 10%-40% of patients with sarcoidosis develop progressive pulmonary disease, and >60% of deaths resulting from sarcoidosis are due to advance cardiopulmonary disease. Oral glucocorticoids are the first line treatment, while methotrexate and azathioprine are considered second and anti-TNF agents are third line treatments that are used solely or as glucocorticoid sparing agents for symptomatic extrapulmonary or pulmonary sarcoidosis with infiltrates on chest radiographs and abnormal PFT. Relapse rates have ranged from...
Source: Journal of Autoimmunity - October 21, 2023 Category: Allergy & Immunology Authors: John A Belperio Michael C Fishbein Fereidoun Abtin Jessica Channick Shailesh A Balasubramanian Joseph P Lynch Iii Source Type: research
Genetic predisposition to sarcoidosis
J Autoimmun. 2023 Oct 19:103122. doi: 10.1016/j.jaut.2023.103122. Online ahead of print.ABSTRACTSarcoidosis is a complex systemic disease with clinical heterogeneity based on varying phenotypes and natural history. The detailed etiology of sarcoidosis remains unknown, but genetic predisposition as well as environmental exposures play a significant role in disease pathogenesis. We performed a comprehensive review of germline genetic (DNA) and transcriptomic (RNA) studies of sarcoidosis, including both previous studies and more recent findings. In this review, we provide an assessment of the following: genetic variants in sa...
Source: Journal of Autoimmunity - October 21, 2023 Category: Allergy & Immunology Authors: Shu-Yi Liao Tasha Fingerlin Lisa Maier Source Type: research
Pulmonary sarcoidosis: A comprehensive review: Past to present
CONCLUSION: The mortality rate for sarcoidosis over a 5 year follow up is approximately 7%. Unfortunately, 10%-40% of patients with sarcoidosis develop progressive pulmonary disease, and >60% of deaths resulting from sarcoidosis are due to advance cardiopulmonary disease. Oral glucocorticoids are the first line treatment, while methotrexate and azathioprine are considered second and anti-TNF agents are third line treatments that are used solely or as glucocorticoid sparing agents for symptomatic extrapulmonary or pulmonary sarcoidosis with infiltrates on chest radiographs and abnormal PFT. Relapse rates have ranged from...
Source: Journal of Autoimmunity - October 21, 2023 Category: Allergy & Immunology Authors: John A Belperio Michael C Fishbein Fereidoun Abtin Jessica Channick Shailesh A Balasubramanian Joseph P Lynch Iii Source Type: research
Genetic predisposition to sarcoidosis
J Autoimmun. 2023 Oct 19:103122. doi: 10.1016/j.jaut.2023.103122. Online ahead of print.ABSTRACTSarcoidosis is a complex systemic disease with clinical heterogeneity based on varying phenotypes and natural history. The detailed etiology of sarcoidosis remains unknown, but genetic predisposition as well as environmental exposures play a significant role in disease pathogenesis. We performed a comprehensive review of germline genetic (DNA) and transcriptomic (RNA) studies of sarcoidosis, including both previous studies and more recent findings. In this review, we provide an assessment of the following: genetic variants in sa...
Source: Journal of Autoimmunity - October 21, 2023 Category: Allergy & Immunology Authors: Shu-Yi Liao Tasha Fingerlin Lisa Maier Source Type: research
Pulmonary sarcoidosis: A comprehensive review: Past to present
CONCLUSION: The mortality rate for sarcoidosis over a 5 year follow up is approximately 7%. Unfortunately, 10%-40% of patients with sarcoidosis develop progressive pulmonary disease, and >60% of deaths resulting from sarcoidosis are due to advance cardiopulmonary disease. Oral glucocorticoids are the first line treatment, while methotrexate and azathioprine are considered second and anti-TNF agents are third line treatments that are used solely or as glucocorticoid sparing agents for symptomatic extrapulmonary or pulmonary sarcoidosis with infiltrates on chest radiographs and abnormal PFT. Relapse rates have ranged from...
Source: Journal of Autoimmunity - October 21, 2023 Category: Allergy & Immunology Authors: John A Belperio Michael C Fishbein Fereidoun Abtin Jessica Channick Shailesh A Balasubramanian Joseph P Lynch Iii Source Type: research
Genetic predisposition to sarcoidosis
J Autoimmun. 2023 Oct 19:103122. doi: 10.1016/j.jaut.2023.103122. Online ahead of print.ABSTRACTSarcoidosis is a complex systemic disease with clinical heterogeneity based on varying phenotypes and natural history. The detailed etiology of sarcoidosis remains unknown, but genetic predisposition as well as environmental exposures play a significant role in disease pathogenesis. We performed a comprehensive review of germline genetic (DNA) and transcriptomic (RNA) studies of sarcoidosis, including both previous studies and more recent findings. In this review, we provide an assessment of the following: genetic variants in sa...
Source: Journal of Autoimmunity - October 21, 2023 Category: Allergy & Immunology Authors: Shu-Yi Liao Tasha Fingerlin Lisa Maier Source Type: research
Pulmonary sarcoidosis: A comprehensive review: Past to present
CONCLUSION: The mortality rate for sarcoidosis over a 5 year follow up is approximately 7%. Unfortunately, 10%-40% of patients with sarcoidosis develop progressive pulmonary disease, and >60% of deaths resulting from sarcoidosis are due to advance cardiopulmonary disease. Oral glucocorticoids are the first line treatment, while methotrexate and azathioprine are considered second and anti-TNF agents are third line treatments that are used solely or as glucocorticoid sparing agents for symptomatic extrapulmonary or pulmonary sarcoidosis with infiltrates on chest radiographs and abnormal PFT. Relapse rates have ranged from...
Source: Journal of Autoimmunity - October 21, 2023 Category: Allergy & Immunology Authors: John A Belperio Michael C Fishbein Fereidoun Abtin Jessica Channick Shailesh A Balasubramanian Joseph P Lynch Iii Source Type: research
Genetic predisposition to sarcoidosis
J Autoimmun. 2023 Oct 19:103122. doi: 10.1016/j.jaut.2023.103122. Online ahead of print.ABSTRACTSarcoidosis is a complex systemic disease with clinical heterogeneity based on varying phenotypes and natural history. The detailed etiology of sarcoidosis remains unknown, but genetic predisposition as well as environmental exposures play a significant role in disease pathogenesis. We performed a comprehensive review of germline genetic (DNA) and transcriptomic (RNA) studies of sarcoidosis, including both previous studies and more recent findings. In this review, we provide an assessment of the following: genetic variants in sa...
Source: Journal of Autoimmunity - October 21, 2023 Category: Allergy & Immunology Authors: Shu-Yi Liao Tasha Fingerlin Lisa Maier Source Type: research
Circulating T cells in sarcoidosis have an aberrantly activated phenotype that correlates with disease outcome
CONCLUSIONS: Circulating T cell subpopulations of sarcoidosis patients display phenotypic abnormalities that correlate with disease outcome, supporting a critical role of aberrant T cell activation in sarcoidosis pathogenesis.PMID:37863732 | DOI:10.1016/j.jaut.2023.103120 (Source: Journal of Autoimmunity)
Source: Journal of Autoimmunity - October 20, 2023 Category: Allergy & Immunology Authors: Jelle R Miedema Lieke J de Jong Denise van Uden Ingrid M Bergen Mirjam Kool Caroline E Broos Vivienne Kahlmann Marlies S Wijsenbeek Rudi W Hendriks Odilia B J Corneth Source Type: research
Circulating T cells in sarcoidosis have an aberrantly activated phenotype that correlates with disease outcome
CONCLUSIONS: Circulating T cell subpopulations of sarcoidosis patients display phenotypic abnormalities that correlate with disease outcome, supporting a critical role of aberrant T cell activation in sarcoidosis pathogenesis.PMID:37863732 | DOI:10.1016/j.jaut.2023.103120 (Source: Journal of Autoimmunity)
Source: Journal of Autoimmunity - October 20, 2023 Category: Allergy & Immunology Authors: Jelle R Miedema Lieke J de Jong Denise van Uden Ingrid M Bergen Mirjam Kool Caroline E Broos Vivienne Kahlmann Marlies S Wijsenbeek Rudi W Hendriks Odilia B J Corneth Source Type: research
Rapamycin nanoparticles increase the therapeutic window of engineered interleukin-2 and drive expansion of antigen-specific regulatory T cells for protection against autoimmune disease
J Autoimmun. 2023 Oct 14;140:103125. doi: 10.1016/j.jaut.2023.103125. Online ahead of print.ABSTRACTInterleukin-2 (IL-2) therapies targeting the high affinity IL-2 receptor expressed on regulatory T cells (Tregs) have shown promising therapeutic benefit in autoimmune diseases through nonselective expansion of pre-existing Treg populations, but are potentially limited by the inability to induce antigen-specific Tregs, as well as by dose-limiting activation of effector immune cells in settings of inflammation. We recently developed biodegradable nanoparticles encapsulating rapamycin, called ImmTOR, which induce selective imm...
Source: Journal of Autoimmunity - October 16, 2023 Category: Allergy & Immunology Authors: Takashi Kei Kishimoto Max Fournier Alicia Michaud Gina Rizzo Christopher Roy Teresa Capela Natasha Nukolova Ning Li Liam Doyle Fen-Ni Fu Derek VanDyke Peter G Traber Jamie B Spangler Sheldon S Leung Petr O Ilyinskii Source Type: research
Rapamycin nanoparticles increase the therapeutic window of engineered interleukin-2 and drive expansion of antigen-specific regulatory T cells for protection against autoimmune disease
J Autoimmun. 2023 Oct 14;140:103125. doi: 10.1016/j.jaut.2023.103125. Online ahead of print.ABSTRACTInterleukin-2 (IL-2) therapies targeting the high affinity IL-2 receptor expressed on regulatory T cells (Tregs) have shown promising therapeutic benefit in autoimmune diseases through nonselective expansion of pre-existing Treg populations, but are potentially limited by the inability to induce antigen-specific Tregs, as well as by dose-limiting activation of effector immune cells in settings of inflammation. We recently developed biodegradable nanoparticles encapsulating rapamycin, called ImmTOR, which induce selective imm...
Source: Journal of Autoimmunity - October 16, 2023 Category: Allergy & Immunology Authors: Takashi Kei Kishimoto Max Fournier Alicia Michaud Gina Rizzo Christopher Roy Teresa Capela Natasha Nukolova Ning Li Liam Doyle Fen-Ni Fu Derek VanDyke Peter G Traber Jamie B Spangler Sheldon S Leung Petr O Ilyinskii Source Type: research
Rapamycin nanoparticles increase the therapeutic window of engineered interleukin-2 and drive expansion of antigen-specific regulatory T cells for protection against autoimmune disease
J Autoimmun. 2023 Oct 14;140:103125. doi: 10.1016/j.jaut.2023.103125. Online ahead of print.ABSTRACTInterleukin-2 (IL-2) therapies targeting the high affinity IL-2 receptor expressed on regulatory T cells (Tregs) have shown promising therapeutic benefit in autoimmune diseases through nonselective expansion of pre-existing Treg populations, but are potentially limited by the inability to induce antigen-specific Tregs, as well as by dose-limiting activation of effector immune cells in settings of inflammation. We recently developed biodegradable nanoparticles encapsulating rapamycin, called ImmTOR, which induce selective imm...
Source: Journal of Autoimmunity - October 16, 2023 Category: Allergy & Immunology Authors: Takashi Kei Kishimoto Max Fournier Alicia Michaud Gina Rizzo Christopher Roy Teresa Capela Natasha Nukolova Ning Li Liam Doyle Fen-Ni Fu Derek VanDyke Peter G Traber Jamie B Spangler Sheldon S Leung Petr O Ilyinskii Source Type: research
Rapamycin nanoparticles increase the therapeutic window of engineered interleukin-2 and drive expansion of antigen-specific regulatory T cells for protection against autoimmune disease
J Autoimmun. 2023 Oct 14;140:103125. doi: 10.1016/j.jaut.2023.103125. Online ahead of print.ABSTRACTInterleukin-2 (IL-2) therapies targeting the high affinity IL-2 receptor expressed on regulatory T cells (Tregs) have shown promising therapeutic benefit in autoimmune diseases through nonselective expansion of pre-existing Treg populations, but are potentially limited by the inability to induce antigen-specific Tregs, as well as by dose-limiting activation of effector immune cells in settings of inflammation. We recently developed biodegradable nanoparticles encapsulating rapamycin, called ImmTOR, which induce selective imm...
Source: Journal of Autoimmunity - October 16, 2023 Category: Allergy & Immunology Authors: Takashi Kei Kishimoto Max Fournier Alicia Michaud Gina Rizzo Christopher Roy Teresa Capela Natasha Nukolova Ning Li Liam Doyle Fen-Ni Fu Derek VanDyke Peter G Traber Jamie B Spangler Sheldon S Leung Petr O Ilyinskii Source Type: research
